|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-4-21
|
|
pubmed:abstractText |
Gefitinib (Iressa) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
780-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15728108-Adult,
pubmed-meshheading:15728108-Aged,
pubmed-meshheading:15728108-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15728108-Chemotherapy, Adjuvant,
pubmed-meshheading:15728108-Confidence Intervals,
pubmed-meshheading:15728108-Dose-Response Relationship, Drug,
pubmed-meshheading:15728108-Drug Administration Schedule,
pubmed-meshheading:15728108-Exanthema,
pubmed-meshheading:15728108-Female,
pubmed-meshheading:15728108-Humans,
pubmed-meshheading:15728108-Lung Neoplasms,
pubmed-meshheading:15728108-Male,
pubmed-meshheading:15728108-Middle Aged,
pubmed-meshheading:15728108-Neoplasm Staging,
pubmed-meshheading:15728108-Pneumonectomy,
pubmed-meshheading:15728108-Predictive Value of Tests,
pubmed-meshheading:15728108-Probability,
pubmed-meshheading:15728108-Prognosis,
pubmed-meshheading:15728108-Prospective Studies,
pubmed-meshheading:15728108-Quinazolines,
pubmed-meshheading:15728108-Risk Assessment,
pubmed-meshheading:15728108-Salvage Therapy,
pubmed-meshheading:15728108-Statistics, Nonparametric,
pubmed-meshheading:15728108-Survival Analysis,
pubmed-meshheading:15728108-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|
